Immune landscape and a promising immune prognostic model associated with TP53 in early‐stage lung adenocarcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune landscape and a promising immune prognostic model associated with TP53 in early‐stage lung adenocarcinoma
Authors
Keywords
-
Journal
Cancer Medicine
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-12-12
DOI
10.1002/cam4.3655
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma
- (2020) Dina Guo et al. Journal of Translational Medicine
- The characteristics and nomogram for primary lung papillary adenocarcinoma
- (2020) Yuqian Zhang et al. Open Medicine
- Cancer type-dependent correlations between TP53 mutations and antitumor immunity
- (2020) Lin Li et al. DNA REPAIR
- Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma
- (2020) Xuanwen Bao et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Mast cell‐based molecular subtypes and signature associated with clinical outcome in early‐stage lung adenocarcinoma
- (2020) Xuanwen Bao et al. Molecular Oncology
- Immunoscore Predicts Survival in Early-Stage Lung Adenocarcinoma Patients
- (2020) Zihuan Zhao et al. Frontiers in Oncology
- Integrative Proteomic Characterization of Human Lung Adenocarcinoma
- (2020) Jun-Yu Xu et al. CELL
- Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression
- (2020) Tyler J. Alban et al. Frontiers in Immunology
- TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival
- (2020) Donald Freudenstein et al. Cancers
- CXCR4/MIF axis amplifies tumor growth and epithelial-mesenchymal interaction in non-small cell lung cancer
- (2020) Benedikt Jäger et al. CELLULAR SIGNALLING
- Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma
- (2020) Pancheng Wu et al. Journal of Translational Medicine
- Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap
- (2019) Jüri Reimand et al. Nature Protocols
- Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma
- (2019) Junyu Long et al. EBioMedicine
- Mutation Profile of Resected EGFR‐Mutated Lung Adenocarcinoma by Next‐Generation Sequencing
- (2019) Ze‐Rui Zhao et al. ONCOLOGIST
- MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential
- (2019) Justin C. Penticuff et al. Nature Reviews Urology
- Cisplatin resistant lung cancer cells promoted M2 polarization of tumor-associated macrophages via the Src/CD155/MIF functional pathway
- (2019) Wen-Chien Huang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Interleukin-1β provided by KIT-competent mast cells is required for KRAS-mutant lung adenocarcinoma
- (2019) Ioannis Lilis et al. OncoImmunology
- The immunobiology of MIF: function, genetics and prospects for precision medicine
- (2019) Insoo Kang et al. Nature Reviews Rheumatology
- A Robust 8-Gene Prognostic Signature for Early-Stage Non-small Cell Lung Cancer
- (2019) Ru He et al. Frontiers in Oncology
- Genomic and immune profiling of pre-invasive lung adenocarcinoma
- (2019) Haiquan Chen et al. Nature Communications
- Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: A systematic review and meta‐analysis
- (2019) Ziying Zhang et al. Cancer Medicine
- TP53,STK11andEGFRMutations Predict Tumor Immune Profile and the Response to anti-PD-1 in Lung Adenocarcinoma
- (2018) Jerome Biton et al. CLINICAL CANCER RESEARCH
- The Immune Landscape of Cancer
- (2018) Vésteinn Thorsson et al. IMMUNITY
- Claudin-18–mediated YAP activity regulates lung stem and progenitor cell homeostasis and tumorigenesis
- (2018) Beiyun Zhou et al. JOURNAL OF CLINICAL INVESTIGATION
- Frontline immunotherapy for NSCLC: alone or not alone?
- (2018) Cesare Gridelli et al. Nature Reviews Clinical Oncology
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Practical Guide to Surgical Data Sets: Surveillance, Epidemiology, and End Results (SEER) Database
- (2018) Kemi M. Doll et al. JAMA Surgery
- Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
- (2018) Nicolas Coudray et al. NATURE MEDICINE
- Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
- (2018) Hongshu Sui et al. Journal of Immunology Research
- gwasurvivr: an R package for genome-wide survival analysis
- (2018) Abbas A Rizvi et al. BIOINFORMATICS
- Mutant p53 as a guardian of the cancer cell
- (2018) Fiamma Mantovani et al. CELL DEATH AND DIFFERENTIATION
- Development and validation of an immune gene-set based Prognostic signature in ovarian cancer
- (2018) Sipeng Shen et al. EBioMedicine
- MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics
- (2017) Pathricia V. Tilstam et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)
- (2017) Solange Peters et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy
- (2017) Xuetian Yue et al. JOURNAL OF MOLECULAR BIOLOGY
- Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
- (2017) Kanaga Sabapathy et al. Nature Reviews Clinical Oncology
- Potential role of P2X7R in esophageal squamous cell carcinoma proliferation
- (2017) André A Santos et al. Purinergic Signalling
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma
- (2017) David Kung-Chun Chiu et al. Nature Communications
- EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
- (2017) Zhong-Yi Dong et al. OncoImmunology
- Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
- (2016) H. Kadara et al. ANNALS OF ONCOLOGY
- Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
- (2016) Zhong-Yi Dong et al. CLINICAL CANCER RESEARCH
- Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers
- (2016) Ingrid Lua et al. JOURNAL OF HEPATOLOGY
- Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases
- (2016) Simone BSP Terra et al. MODERN PATHOLOGY
- Comprehensive Immune Profiling of Lung Adenocarcinomas Reveals Four Immunosubtypes with Plasma Cell Subtype a Negative Indicator
- (2016) Y. Kurebayashi et al. Cancer Immunology Research
- Macrophage migration inhibitory factor: A key cytokine and therapeutic target in colon cancer
- (2015) A.N. Gordon-Weeks et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer
- (2015) Kurt A. Schalper et al. JNCI-Journal of the National Cancer Institute
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- (2015) Matthew E. Ritchie et al. NUCLEIC ACIDS RESEARCH
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer
- (2015) Kurt A. Schalper et al. JNCI-Journal of the National Cancer Institute
- Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma
- (2014) Camila S Oliveira et al. BMC CANCER
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
- (2012) Guangchuang Yu et al. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
- Tumor-derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation
- (2011) Claudia A. Dumitru et al. INTERNATIONAL JOURNAL OF CANCER
- Overexpression of NTPDase2 in gliomas promotes systemic inflammation and pulmonary injury
- (2011) Elizandra Braganhol et al. Purinergic Signalling
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
- (2009) M. D. Robinson et al. BIOINFORMATICS
- Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer
- (2008) Xiangdong Xu et al. CANCER LETTERS
- How To Build and Interpret a Nomogram for Cancer Prognosis
- (2008) Alexia Iasonos et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now